title: Post-transfusion hepatitis revisited.
abstract: OBJECTIVE
  To evaluate the risk of post-transfusion and postoperative non-A non-B hepatitis in Australia immediately before the introduction of screening for hepatitis C.
  
  
  METHODS
  Retrospective testing of blood samples from a prospective study of cardiac surgery patients. Samples were taken from transfusion recipients and non-transfused controls at regular intervals for 12 months after surgery during 1987-1989. For all donor, recipient and control samples, alanine aminotransferase (ALT) levels were measured and tests for antibody to hepatitis B (anti-HBc, anti-HBs) and, when available, to hepatitis C (anti-HCV) were performed.
  
  
  METHODS
  Cardiac surgery units.
  
  
  METHODS
  Participants were included if they lived in the metropolitan area, and had not had a transfusion in the past year.
  
  
  METHODS
  Post-transfusion hepatitis (two consecutive samples showing raised ALT levels, > 90 IU/L with no other known cause); hepatitis C infection and carriage (antibody to hepatitis C).
  
  
  RESULTS
  Post-transfusion hepatitis occurred in 1.1% of 736 recipients of blood not screened for hepatitis C (i.e., two cases per 1000 unscreened units given). No hepatitis occurred in 514 controls. Seven of the eight patients with post-transfusion hepatitis seroconverted to hepatitis C virus infection. Seven of the 26 anti-HCV-positive donations transmitted hepatitis C, six of these were positive by recombinant immunoblot assay (RIBA) (one by second generation testing only) and one was RIBA indeterminate. Nineteen were RIBA non-reactive; one transmitted hepatitis but the recipient did not develop anti-HCV, although hepatitis C RNA was detected in the donation. Serum ALT was raised in four of the six infective donations.
  
  
  CONCLUSIONS
  Hepatitis C virus infection accounted for almost all cases of non-A non-B post-transfusion hepatitis. First generation anti-HCV tests detected about 85% of infective donations. Surrogate testing of donations by ALT or anti-HBc offers no additional advantage.
authors.affiliation: Australian Red Cross Society Blood Transfusion Service, Sydney, NSW.
authors.forename: S L
authors.initials: SL
authors.lastname: Ismay
authors.forename: S
authors.initials: S
authors.lastname: Thomas
authors.forename: A
authors.initials: A
authors.lastname: Fellows
authors.forename: A
authors.initials: A
authors.lastname: Keller
authors.forename: K G
authors.initials: KG
authors.lastname: Kenrick
authors.forename: G T
authors.initials: GT
authors.lastname: Archer
authors.forename: B R
authors.initials: BR
authors.lastname: Wylie
authors.forename: Y E
authors.initials: YE
authors.lastname: Cossart
mesh_terms: D000410:Alanine Transaminase / Q000097:blood; D001782:Blood Donors; D006348:Cardiac Surgical Procedures; D016174:Hepacivirus / Q000276:immunology; D006508:Hepatitis Antibodies / Q000032:analysis; D006526:Hepatitis C / Q000453:epidemiology / Q000209:etiology* / Q000276:immunology; D018937:Hepatitis C Antibodies; D006801:Humans; D009517:New South Wales / Q000453:epidemiology; D011446:Prospective Studies; D012189:Retrospective Studies; D065227:Transfusion Reaction; D014904:Western Australia / Q000453:epidemiology
chemical_list: D006508:Hepatitis Antibodies; D018937:Hepatitis C Antibodies; D000410:Alanine Transaminase